8. Massive Transfusion Protocol (Revised — PROPPR, CRYOSTAT-2, CRASH-2/3)

Quick Recap

Tier 1 expansion protocol — Hematology System. This is a REVISED version of the existing "Massive Transfusion" protocol (7/8), incorporating recent landmark trial evidence (PROPPR, CRYOSTAT-2, CRASH-2/3) not present in the original build. Please compare against the existing page and archive/replace as appropriate — the notion-update-page tool is not reliable for large content edits, so this was built as a new page per established workflow. Shares core damage control resuscitation principles with the Hypovolemic Shock protocol (Cardiovascular System); this protocol focuses on transfusion-specific ratios, adjuncts, and monitoring.

1. Definition

Massive transfusion is classically defined as ≥10 units of packed red blood cells (RBC) within 24 hours, or ≥4 units within 1 hour with anticipated ongoing need, though these fixed-volume definitions are increasingly recognized as retrospective and lagging — by the time 10 units have been given, the critical early resuscitation decisions have already been made.

Massive Transfusion Protocol (MTP): an institutional, pre-activated pathway that delivers blood products in fixed ratios rapidly and continuously, without waiting for individual product requests or real-time laboratory results, to a patient with active life-threatening hemorrhage.

Damage control resuscitation (DCR): the broader strategy within which MTP sits — permissive hypotension, early balanced blood product administration (minimizing crystalloid), and rapid hemorrhage source control, aimed at interrupting the "lethal triad" of coagulopathy, hypothermia, and acidosis before it becomes self-perpetuating.

Predicting the need for MTP (to trigger activation before the 10-unit threshold is reached): scores such as the Assessment of Blood Consumption (ABC) score and Shock Index (HR/SBP >0.9–1.0) are used for early activation; clinical gestalt in the presence of ongoing hemorrhage with hemodynamic instability should not be delayed pending a formal score.

2. Pathophysiology

Trauma-induced coagulopathy (TIC) develops rapidly and is distinct from simple dilutional coagulopathy from fluid administration — it is present in up to a third of severely injured patients even before significant fluid resuscitation, driven by tissue injury, shock-induced hypoperfusion, and activation of the protein C pathway, producing a combination of impaired thrombin generation, hyperfibrinolysis, and platelet dysfunction.

The lethal triad: coagulopathy, hypothermia, and acidosis form a self-amplifying cycle — hypothermia impairs enzymatic clotting factor function and platelet activity; acidosis further impairs clotting factor activity and platelet function; both worsen ongoing coagulopathy, which perpetuates bleeding, which worsens shock, hypothermia, and acidosis in turn. Breaking this cycle requires simultaneous attention to all three, not sequential correction.

Fibrinogen is typically the first coagulation factor to fall to critically low levels in major hemorrhage — up to a third of trauma patients have fibrinogen <2 g/L on admission, rising to as many as 75% in more severe cohorts, making it a specific and early target for replacement, though how best to replace it (empirically vs. guided) remains an active area of investigation (Section 22).

Dilutional coagulopathy: large-volume crystalloid or RBC-only resuscitation without concurrent plasma/platelet replacement dilutes remaining clotting factors and platelets, compounding trauma-induced coagulopathy — this is the mechanistic rationale for balanced-ratio transfusion over RBC-predominant strategies.

Hyperfibrinolysis: a subset of severely injured, shocked patients develop pathological acceleration of clot breakdown, contributing to ongoing hemorrhage — the rationale for early antifibrinolytic (tranexamic acid) administration.

3. Immediate Stabilization (ABCDE) — MTP Activation Context

Airway

Breathing

Circulation

Disability

Exposure

Decision point: MTP activation, tranexamic acid administration, and hemorrhage source control pursuit should occur in parallel, not sequentially — delay in any one component compounds the lethal triad.

4. Focused History

• Mechanism and time of injury/bleeding onset (critical for TXA timing window — Section 11)
• Anticoagulant/antiplatelet medication use (informs reversal strategy, cross-reference Coagulopathy protocol)
• Known bleeding diathesis or hematologic condition
• Prior transfusion history/reactions, known antibodies
• Estimated blood loss and rate of ongoing loss
• Non-trauma massive hemorrhage context if applicable (postpartum hemorrhage, GI bleeding, ruptured aneurysm, post-surgical bleeding — cross-reference relevant disease-specific protocols; MTP principles apply across etiologies, not only trauma)

5. Comprehensive System-wise Examination

• Cardiovascular: heart rate, blood pressure trend, capillary refill, peripheral pulses
• Respiratory: work of breathing, evidence of hemothorax
• Abdomen: distension, rigidity (occult intra-abdominal hemorrhage)
• Pelvis: instability (pelvic hemorrhage source)
• Extremities: obvious external hemorrhage, long bone deformity
• Skin: pallor, mottling, temperature (hypothermia assessment)

POCUS integration: eFAST (extended Focused Assessment with Sonography in Trauma) to rapidly identify hemoperitoneum, hemothorax, and pericardial effusion/tamponade as occult hemorrhage sources requiring urgent source control.

6. Syndrome Identification

• Hemorrhagic shock, trauma-related
• Hemorrhagic shock, non-trauma (obstetric, GI, post-surgical, ruptured vascular pathology — cross-reference relevant protocols)
• Trauma-induced coagulopathy (present or evolving)
• Lethal triad (established or at risk)

7. Differential Diagnosis (of Ongoing Bleeding Despite MTP)

Life-threatening / must-not-miss:

• Uncontrolled surgical/anatomical bleeding source not yet addressed
• Undiagnosed coagulopathy from anticoagulant medication
• Hyperfibrinolysis not adequately treated
• Severe hypocalcemia impairing clot formation (citrate toxicity from rapid transfusion — Section 11)

Common causes of apparent refractoriness:

• Inadequate ratio (RBC-predominant rather than balanced)
• Ongoing hypothermia/acidosis not corrected
• Undertreated fibrinogen deficiency

Iatrogenic: delayed MTP activation, excessive crystalloid administration diluting coagulation factors, inadequate warming

8. Severity Assessment

• ABC score (Assessment of Blood Consumption): penetrating mechanism, positive FAST, SBP ≤90 mmHg, HR ≥120 — ≥2 positive predicts MTP need, used for early activation
• Shock Index (HR/SBP): >0.9–1.0 associated with increased transfusion requirement and mortality
• Viscoelastic testing (TEG/ROTEM): provides real-time, whole-blood functional coagulation assessment (clot formation, strength, fibrinolysis) faster than conventional coagulation labs (PT/INR/aPTT, which reflect plasma-only, not whole-blood, hemostatic function) — increasingly used to guide targeted product administration alongside or in place of empirical fixed-ratio protocols in some centers (Section 22, ITACTIC trial)
• Serial lactate and base deficit: markers of shock severity and resuscitation adequacy, trending rather than single values

9. Investigations

Immediate bedside: point-of-care hemoglobin/hematocrit, blood gas (lactate, base deficit), point-of-care viscoelastic testing where available

Routine labs: CBC, coagulation profile (PT/INR, aPTT, fibrinogen), electrolytes (ionized calcium — critical during massive transfusion), type and crossmatch

Repeat frequency: repeat CBC, coagulation profile, and ionized calcium approximately every 4–6 units of blood product transfused (or per institutional MTP protocol), and with any change in clinical trajectory

Do not let laboratory turnaround time delay MTP activation or initial balanced-ratio transfusion — this is the entire rationale for empirical fixed-ratio protocols rather than lab-guided-only strategies in the initial resuscitation phase.

10. Point-of-Care Ultrasound

eFAST: rapid identification of hemoperitoneum, hemothorax, pericardial effusion as occult hemorrhage sources — directly informs urgency and target of surgical/procedural source control.

Cardiac: assess for tamponade physiology, and to distinguish ongoing hemorrhagic shock from a co-existing cardiogenic component in complex or prolonged resuscitations.

Viscoelastic testing (TEG/ROTEM), while not strictly "ultrasound," functions as the analogous real-time point-of-care functional test for the coagulation system in this protocol and is discussed in Section 8.

11. Evidence-Based Management

Transfusion Ratio — The Core of MTP

• Target ratio: 1:1:1 to 1:1:2 (plasma:platelets:RBC) — balanced transfusion strategy, delivered in pre-packaged "packs" (e.g., 6 RBC : 6 plasma : 1 apheresis platelet unit) to operationalize the ratio without requiring real-time calculation under pressure
• PROPPR trial (Holcomb et al., JAMA 2015, n=680): compared 1:1:1 vs. 1:1:2 — no significant difference in 24-hour or 30-day mortality (13% vs. 17% at 24h; 22% vs. 26% at 30 days), but significantly fewer patients in the 1:1:1 group died from exsanguination (9.2% vs. 14.6%) and significantly more achieved hemostasis (86% vs. 78%), with no increase in ARDS, MOF, VTE, sepsis, or transfusion-related complications — this underlies the current standard of adopting 1:1:1 (or between 1:1:1 and 1:1:2) as the default ratio
• Time to blood product delivery matters independently of ratio — faster delivery is consistently associated with better outcomes, reinforcing the value of a pre-activated, non-request-based protocol

Tranexamic Acid (TXA)

• CRASH-2 trial (Lancet 2010, n=20,211 trauma patients with/at risk of significant hemorrhage): TXA (1g bolus over 10 min, then 1g over 8h) reduced all-cause mortality (14.5% vs. 16.0%; RR 0.91, 95% CI 0.85–0.97) and death specifically due to bleeding (4.9% vs. 5.7%; RR 0.85, 95% CI 0.76–0.96) — benefit is time-critical: administer within 3 hours of injury; a nested analysis found the survival benefit decreases by ~10% for every 15 minutes of treatment delay up to 3 hours, after which benefit is not established and TXA given beyond 3 hours may be harmful in trauma
• CRASH-3 trial (Lancet 2019, TBI-specific): TXA within 3 hours reduced head-injury-related death overall (non-significant trend, RR 0.94), but with a significant reduction specifically in mild-to-moderate TBI (GCS 9–15; RR 0.78, 95% CI 0.64–0.95) and no apparent benefit in severe TBI (GCS 3–8; RR 0.99) — TXA was safe with no increase in vascular occlusive events or seizures; early treatment in mild-moderate TBI is now supported, while benefit in severe TBI remains unproven
• Practical synthesis: give TXA as early as possible, ideally prehospital or immediately on arrival, in any patient with significant traumatic hemorrhage or TBI within the 3-hour window; do not give beyond 3 hours from injury in trauma

Fibrinogen Replacement — An Area of Genuine Recent Practice-Changing Evidence

• CRYOSTAT-2 trial (Davenport et al., JAMA 2023, n=1,573, UK/US major trauma centers): tested early, empirical, high-dose cryoprecipitate (3 pools, ~6g fibrinogen) added to standard 1:1:1 MTP, versus standard care with cryoprecipitate given later per usual clinical judgment/labs — no difference in 28-day all-cause mortality (25.3% vs. 26.1%; OR 0.96, 95% CI 0.75–1.23) and increased blood component exposure in the empirical group
• Clinical implication: empirical early high-dose cryoprecipitate for all MTP-activated patients is not supported by this trial and should not be adopted as a universal default — the negative result likely reflects that a substantial proportion of an unselected MTP population does not actually have significant hypofibrinogenemia, diluting any true treatment effect; the trial supports a more targeted, viscoelastic/fibrinogen-level-guided approach to cryoprecipitate/fibrinogen concentrate administration rather than empirical dosing for every activation, though standard MTP packs (typically including cryoprecipitate in later packs) remain reasonable practice pending further refinement of patient selection
• Fibrinogen concentrate vs. cryoprecipitate: mechanistically comparable fibrinogen sources; choice is largely institution/availability-dependent

Calcium Replacement

• Citrate in stored blood products chelates ionized calcium; rapid, high-volume transfusion causes clinically significant hypocalcemia, which independently impairs clot formation (compounding coagulopathy) and myocardial contractility
• Monitor ionized calcium serially during MTP and replace proactively (calcium chloride preferred over calcium gluconate for more rapid and reliable correction in this setting) rather than waiting for severe hypocalcemia to manifest

Damage Control Resuscitation Principles (Integrated Throughout)

• Permissive hypotension until hemorrhage control (Section 3), except in TBI
• Minimize crystalloid administration
• Active, aggressive warming from the outset
• Early, parallel pursuit of definitive hemorrhage source control (surgical, endovascular, endoscopic, or obstetric as etiology dictates) — MTP does not substitute for source control

Whole Blood (Emerging/Expanding Practice)

• Low-titer O whole blood (LTOWB) is increasingly used, particularly in military and prehospital/early civilian trauma settings, as a single-product alternative that inherently delivers a balanced ratio of RBC, plasma, and platelets in one unit, simplifying logistics and potentially reducing time to balanced resuscitation
• Evidence base is growing but less extensive than for component-based 1:1:1 therapy; availability varies substantially by institution and region

12. Organ Support

• Cardiovascular: vasopressor support may be needed as a bridge during ongoing resuscitation but should not substitute for adequate blood product/volume replacement in hemorrhagic shock (cross-reference Vasopressor & Inotrope Selection & Titration protocol — note hemorrhagic shock is not a primary vasopressor-indicated shock state; blood products are the definitive therapy)
• Renal: monitor for transfusion-related AKI and rhabdomyolysis-associated renal injury in polytrauma
• Respiratory: monitor for TRALI/TACO (transfusion-related lung injury/circulatory overload) with large-volume transfusion

13. Disease-Specific Therapy

• Tranexamic acid: 1g IV bolus over 10 minutes, then 1g IV over 8 hours, within 3 hours of injury
• Calcium chloride: 1g IV (or per ionized calcium level) proactively during massive transfusion, reassessed every 4–6 units
• Cryoprecipitate/fibrinogen concentrate: per institutional MTP pack composition; consider targeted (viscoelastic/fibrinogen-level-guided) dosing beyond the standard pack rather than routine empirical high-dose supplementation for all activations (Section 11, 22)
• Prothrombin complex concentrate (PCC): for rapid reversal of vitamin K antagonist-associated coagulopathy contributing to hemorrhage (cross-reference Coagulopathy protocol)

14. Consultation Matrix

15. Monitoring Framework

• Clinical: continuous hemodynamic monitoring, core temperature, urine output
• Laboratory: CBC, coagulation profile, ionized calcium, lactate/base deficit every 4–6 units transfused or per institutional protocol
• Escalation triggers: ongoing hemorrhage despite adequate ratio-based transfusion, worsening coagulopathy, refractory hypothermia/acidosis
• De-escalation criteria: hemorrhage source controlled, hemodynamic stability sustained, coagulation parameters normalizing — formally stand down MTP activation per institutional protocol to avoid unnecessary continued product use

16. ICU Bundle Checklist

17. Complications

Early:

• Ongoing exsanguination if ratio inadequate or source control delayed
• Hypocalcemia-related coagulopathy and cardiac dysfunction
• Hypothermia-related coagulopathy
• Transfusion reactions (acute hemolytic, febrile non-hemolytic, TRALI)
• Citrate toxicity

Late:

• Transfusion-associated circulatory overload (TACO)
• ARDS, multiorgan dysfunction (though PROPPR found no increase with balanced-ratio strategy specifically)
• Alloimmunization
• VTE (though not increased with balanced transfusion per PROPPR)

Prevention: early MTP activation, balanced ratio, proactive calcium replacement, aggressive warming, early TXA

Rescue: viscoelastic-guided targeted product administration for refractory coagulopathy; hematology consultation; reassess for an uncontrolled surgical source

18. Escalation & De-escalation

Escalation: persistent hemorrhage despite adequate balanced-ratio MTP → reassess for uncontrolled surgical/anatomical source, consider viscoelastic-guided targeted factor replacement, escalate to more aggressive source control (interventional radiology embolization, damage control surgery, REBOA where available and indicated).

De-escalation: once hemorrhage source is controlled and hemodynamic/coagulation parameters stabilize, formally stand down MTP per institutional protocol; transition to targeted, lab-guided transfusion rather than continued empirical ratio-based dosing.

19. ICU Discharge Criteria (MTP-Relevant Context)

• Hemorrhage source definitively controlled
• Hemodynamic stability without ongoing transfusion requirement
• Coagulation parameters normalized or at an acceptable stable baseline
• Core temperature normalized
• No evidence of ongoing transfusion-related complications requiring ICU-level monitoring

20. Documentation & Medicolegal Checklist

• Time of MTP activation and trigger criteria met (ABC score, Shock Index, or clinical judgment) documented
• Time and dose of TXA administration relative to injury time — critical given the time-dependent efficacy
• Blood product ratios administered and total volumes documented
• Serial laboratory results (coagulation profile, ionized calcium, lactate) documented
• Source control interventions and timing documented
• MTP stand-down time and rationale documented
• Any transfusion reactions documented with management
• Consent/emergency consent documentation per institutional policy for emergency blood product administration

21. Key Guidelines

• European guideline on management of major bleeding and coagulopathy following trauma, 6th edition (Rossaint et al.): comprehensive evidence-based framework for trauma hemorrhage management, including transfusion ratios, TXA timing, and fibrinogen replacement strategy
• Institutional/national massive transfusion protocol guidance (AABB, ISBT) generally endorses the 1:1:1 to 1:1:2 balanced ratio as standard of care based on PROPPR and supporting observational literature

22. Landmark Trials

23. Controversies

• Empirical fixed-ratio vs. viscoelastic (TEG/ROTEM)-guided transfusion: the ITACTIC trial and related literature have not shown a clear, consistent mortality advantage of viscoelastic-guided strategies over well-executed empirical fixed-ratio MTP in the initial resuscitation phase, though viscoelastic guidance may have more value in refining therapy after the initial balanced-ratio phase, once real-time functional data is available — this remains an active area of practice variation rather than a settled question
• CRYOSTAT-2's negative result and fibrinogen replacement strategy: the trial's negative finding does not mean fibrinogen replacement is unimportant — it means unselected, empirical, universal early high-dose dosing is not beneficial and increases product exposure; the more nuanced question of which patients (by viscoelastic signal or fibrinogen level) benefit from targeted early fibrinogen replacement remains unresolved and is the subject of ongoing research (referenced meta-analyses post-CRYOSTAT-2 continue to explore patient selection)
• Optimal ratio — 1:1:1 vs. 1:1:2: PROPPR found no mortality difference between the two ratios, meaning either is defensible; most centers have adopted 1:1:1 based on the secondary exsanguination-death and hemostasis-achievement findings, but this is a less definitive basis than a primary mortality endpoint would provide
• Whole blood vs. component therapy: growing enthusiasm and logistical appeal for LTOWB, but the RCT evidence base directly comparing whole blood to optimized 1:1:1 component therapy in civilian trauma remains less mature than the component-therapy evidence base itself
• TXA beyond the 3-hour window or in non-trauma massive hemorrhage contexts (e.g., GI bleeding, postpartum hemorrhage): the strong evidence base is trauma-specific and time-bound; extrapolation to other hemorrhage contexts should reference the etiology-specific evidence (e.g., WOMAN trial for postpartum hemorrhage) rather than assuming direct generalization from CRASH-2/3

24. References

1. Holcomb JB, Tilley BC, Baraniuk S, et al; PROPPR Study Group. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471-482.
2. Shakur H, Roberts I, Bautista R, et al; CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23-32.
3. Roberts I, Shakur-Still H, Aeron-Thomas A, et al; CRASH-3 trial collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet. 2019;394(10210):1713-1723.
4. Davenport R, Curry N, Fox EE, et al; CRYOSTAT-2 Investigators. Early and empirical high-dose cryoprecipitate for hemorrhage after traumatic injury: the CRYOSTAT-2 randomized clinical trial. JAMA. 2023;330(19):1882-1891.
5. Baksaas-Aasen K, Gall LS, Stensballe J, et al. Viscoelastic haemostatic assay augmented protocols for major trauma haemorrhage (ITACTIC): a randomised, controlled trial. Intensive Care Med. 2021;47(1):49-59.
6. Rossaint R, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition. Crit Care. 2023.
7. Holcomb JB, del Junco DJ, Fox EE, et al; PROMMTT Study Group. The Prospective, Observational, Multicenter, Major Trauma Transfusion (PROMMTT) Study. JAMA Surg. 2013.
8. Burt T, Guilliam A, Davenport R. Effect of early administration of fibrinogen replacement therapy in traumatic haemorrhage: a systematic review and meta-analysis. Crit Care. 2025;29:178.
9. The Washington Manual of Critical Care, 4th ed. 2025 — massive transfusion and coagulopathy chapters.
10. ICU Protocols: A Step-wise Approach, 2nd ed. — relevant transfusion content.